Watchlist Price Alert

Black Diamond Therapeutic... (BDTX)

NASDAQ: BDTX · Real-Time Price · USD

2.27

-0.06 (-2.58%)

At close: Jun 23, 2025, 3:59 PM

2.28

0.24%

Pre-market: Jun 24, 2025, 09:25 AM EDT

-2.58% (1D)

Bid	2.27
Market Cap	129.36M
Revenue (ttm)	70M
Net Income (ttm)	5.09M
EPS (ttm)	0.06
PE Ratio (ttm)	37.92
Forward PE	-2.28
Analyst	Buy

Ask	2.32
Volume	869,629
Avg. Volume (20D)	1,318,248
Open	2.30
Previous Close	2.33
Day's Range	2.15 - 2.31
52-Week Range	1.20 - 6.75
Beta	2.71

About BDTX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol BDTX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for BDTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 months ago

+2.38%

Black Diamond Therapeutics shares are trading high... Unlock content with Pro Subscription

9 months ago

-5.46%

Black Diamond Therapeutics shares are trading higher after the company announced initial Phase 2 data demonstrating encouraging clinical responses and durability of BDTX-1535 in patients with relapsed/refractory epidermal growth factor receptor-mutant non-small cell lung cancer.

News

1 week ago · seekingalpha.com

Black Diamond Therapeutics: Targeted Approach And Early Efficacy Signals Create Potential For Significant Upside

Black Diamond Therapeutics's novel EGFR inhibitor shows promise in addressing resistance mutations in NSCLC and glioblastoma, with key phase 2 data expected in Q4 2025. The Servier licensing deal stre...

3 months ago · seekingalpha.com

Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier

Black Diamond Therapeutics' strategic deal with Servier makes BDTX undervalued, with a $70M upfront payment and potential $710M in milestone payments and royalties. BDTX is trading below its net cash ...